

Special Issue

Anesthesia and Cancer Recurrence: A New Sight

Message from the Guest Editor

Surprisingly, some retrospective studies observed that local anesthetics or intravenous hypnotics injected during oncological interventions improve the overall survival, while opioids and volatiles seem to favor second lesions and recurrences. Nevertheless, further evidence is required to confirm this hypothesis. This Special Issue accepts all manuscripts that deal with analgesia, anesthesia, and surgery from basic to clinical research (original article, review, systematic review, etc.) and that address the recent findings highlighting the benefits, the difficulties, and the future of anesthesia management during the perioperative oncological surgery. Potential topics include, but are not limited to: Future perspectives for anesthesia management during oncological surgery;

Mechanisms of action of anesthetics on tumor cells;
Indications and limits of opioid-free anesthesia;
Advantages and side effects of opioids;
Local and regional anesthesia and relapses;
Advanced strategies to control surgical pain and avoid residual tumor cells;
Mini-invasive procedure and recurrences;
Surgical stress and recurrences.

Guest Editor

Dr. Lucillia Bezu

Institut de Cancerologie Gustave Roussy, Villejuif, France

Deadline for manuscript submissions

closed (5 January 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/174840

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)